Health
U.S. Mylan Becomes 20th Largest Pharmaceutical Company In Romania After Abbott Acquisition
U.S. pharmaceutical company Mylan, which was not directly present in Romania, gained the 20th position in the local pharma players’ ranking after the acquisition of Abbott drug division outs...
Antibiotice To Pay Half Of 2014 Profit As Dividends
Romanian pharmaceutical producer Antibiotice Iasi (ATB.RO) plans to pay dividends of 15.74 million lei (EUR3.5 million), about half of last year’s net profit, according to documents prepared...
Romania, Among Top 5 Emerging Markets For New Terapia Owner Sun Pharma
Sun Pharma group, founded by Dilip Shanghvi, one of India’s wealthiest businessmen, generates sales of over $100 million in Romania, the second largest market in Europe after Russia. Romania...
Gral Medical Opens Two New Clinics In Over EUR1.5M Investment
Romanian private healthcare provider Gral Medical has opened two new clinics this year, in capital Bucharest and in Ploiesti, through an investment worth over EUR1.5 million, and plans to in...
Copaescu, Ponderas: We Did Not Think We’d Need A Double Area In Four Years
The Romanian stakeholders of Bucharest’s Ponderas hospital, specialized in weight loss surgery, invested EUR4 million (RON18 million) in relocation to a new space, with a double capacity.
Value4Capital Might Exit MedLife Shareholding Structure In July-August
The transaction whereby private equity firm Value4Capital (V4C) will exit the shareholding structure of private medical services provider MedLife might be completed in July or August 2015, M...
Adrian Purcarea Leaves Medicover After Less Than Two Years At The Company’s Helm
Adrian Purcarea, 41, the executive who has run private healthcare operator Medicover in the past almost two years, is set to leave this position in May. He will move to America together with...
Antibiotice Iasi 2015 Net Profit Seen Down 32% To RON21.2M
Romanian state-run drugmaker Antibiotice Iasi (ATB.RO) estimates its net profit will fall by 32% to RON21.26 million (nearly EUR4.8 million) in 2015, from RON31.29 million a year before.
Farmaceutica Remedia Proposes Dividends Of RON1.6M, Same As Last Year
Pharmaceutical distributor Farmaceutica Remedia Deva (RMAH.RO) proposes dividends of RON1.59 million (EUR357,800) from its 2014 profit, the same as distributed earnings for 2013.